Compare · CRTX vs RVMD
CRTX vs RVMD
Side-by-side comparison of Cortexyme Inc. (CRTX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRTX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $34.87B.
- RVMD has hit the wire 14 times in the past 4 weeks while CRTX has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 9 for CRTX).
- Company
- Cortexyme Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- -
- $34.87B
- 1M return
- -
- -14.11%
- 1Y return
- -
- +118.83%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 0
- 14
- Recent ratings
- 9
- 25
Cortexyme Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest CRTX
- Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes
- SEC Form 10-Q filed by Cortexyme Inc.
- Cortexyme Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes
- Cortexyme Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Stocks That Hit 52-Week Lows On Thursday
- Recap of Wednesday's Biotech Catalysts - End of The Day Summary
- Stocks That Hit 52-Week Lows On Wednesday
- Cortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022
Latest RVMD
- Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
- Officer Stephen Michael Kelsey exercised 27,160 shares at a strike of $18.56 and sold $4,559,209 worth of shares (27,160 units at $167.86) as part of a pre-agreed trading plan (SEC Form 4)
- Director Flavia Borellini exercised 2,500 shares at a strike of $37.54, increasing direct ownership by 10% to 28,715 units (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)